<DOC>
	<DOC>NCT02439957</DOC>
	<brief_summary>â€¢ To compare the efficacy of brincidofovir (BCV) to valganciclovir (vGCV) for the prevention of CMV disease in kidney transplant recipients who are CMV seropositive pretransplant and received antilymphocyte induction therapy</brief_summary>
	<brief_title>SURPASS: A Randomized, Double-Blind, Multicenter Study of the Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus (CMV) Disease in CMV Seropositive Kidney Transplant Recipients (BCV CMV vGCV)</brief_title>
	<detailed_description />
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>CMV seropositive (R+), who received antilymphocyte induction therapy with antithymocyte globulin (ATG) First or second kidney transplant recipient 14 days posttransplant eGFR &gt; 10mL/min by the CG equation Able to ingest tablets Multi organ transplant recipient Plasma CMV PCR &gt; LOD by the central lab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>